<?xml version='1.0' encoding='UTF-8' ?>
<ec-patent-document file='EC_SP18090693_20181228.xml' country='EC' doc-number='SP18090693' kind='A' date-published='20181228' lang='ES' date-produced='20190116'>
<bibliographic-data id='bibl' doc-number='SP18090693' country='EC' lang='es'>
<publication-reference><document-id ><country>EC</country><doc-number>SP18090693</doc-number><kind>A</kind><date>20181228</date></document-id></publication-reference>
<classification-ipcr><classification-ipc sequence='1'><section> </section><class> </class><subclass> </subclass><main-group> </main-group><subgroup> </subgroup><edition> </edition><ipc-version-indicator><date> </date></ipc-version-indicator><classification-level>C07D401/14_C07D413/12_C07D413/14_A61K31/422_A61K31/4439_A61P1/16_A61P3/04_A61P3/10_A61P29/00_A61P35/00</classification-level><symbol-position> </symbol-position><classification-value> </classification-value></classification-ipc></classification-ipcr>
<application-reference> <document-id><country>EC</country><doc-number>SENADI201890693</doc-number><date>20181206</date></document-id></application-reference>
<priority-claims>
<priority-claim sequence='1' kind='National'><doc-number>62/349,490 </doc-number><date>20160613</date><country>US</country></priority-claim>
</priority-claims>
<parties><applicants>
<applicant sequence='1' designation='all' app-type='applicant'><addressbook><name>GILEAD SCIENCES, INC. </name><address><street>333 Lakeside Drive, Foster City, CA 94404 (US).</street><country>US</country></address></addressbook></applicant>
</applicants>
<inventors>
<inventor sequence='1' designation='all'><addressbook><name>GEGE, Christian</name><address><street>c/o Phenex Pharmaceuticals AG, Donnersbergweg 1, 67059 Ludwigshafen (DE).</street><country>DE</country></address></addressbook></inventor>
<inventor sequence='2' designation='all'><addressbook><name>KROPF, Jeffrey E.</name><address><street>c/o Gilead Sciences Inc., 333 Lakeside Drive, Foster City, CA 94404 (US).</street><country>US</country></address></addressbook></inventor>
<inventor sequence='3' designation='all'><addressbook><name>BLOMGREN, Peter, A.</name><address><street>c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US).</street><country>US</country></address></addressbook></inventor>
<inventor sequence='4' designation='all'><addressbook><name>CURRIE, Kevin, S.</name><address><street>c/o Gilead Sciences Inc., 333 Lakeside Drive, Foster City, CA 94404 (US).</street><country>US</country></address></addressbook></inventor>
<inventor sequence='5' designation='all'><addressbook><name>XU, Jianjun</name><address><street>c/o 4706 147th Place SE Bellevue, WA 98006 (US).</street><country>US</country></address></addressbook></inventor>
</inventors><agents>
<agent sequence='1' rep-type='agent'><addressbook><name>Romoleroux Armijos, María Cecilia </name><address><street>Robles E4-136 y Av. Amazonas, Edif. Proinco Calisto, piso 11, Quito - Ecuador</street><country>EC</country></address></addressbook></agent>
</agents></parties>
<invention-title lang='es'>COMPUESTOS MODULADORES DE FXR (NR1H4)</invention-title>
</bibliographic-data>
<abstract lang='es'>La presente descripción se refiere generalmente a compuestos que se unen al receptor NR1H4 (FXR) y actúan como agonistas de FXR. La descripción se refiere además al uso de los compuestos para la preparación de un medicamento para el tratamiento de enfermedades y/o condiciones a través de la unión de dichos compuestos a dicho receptor nuclear y a un procedimiento para la síntesis de dichos compuestos.</abstract>
</ec-patent-document>
